Serenoa Repens vs. Gestonorone Caproato Nel Trattamento Dell'Ipertrofia Prostatica Benigna * : Studio randomizzato

Wilson J. D. : The pathogenesis of benign prostatic hyperplasia. Amer. J. Med., 68; 745 (1980).

Franks L. M. : Benign nodular hyperplasia of the prostate: a review. Ann. R. Coll. Surg., 14; 92 (1954).

Brendler H. E. : Benign prostatic hyperplasia: natural history. In: Grayhack J. T. , Wilson J. D. , Scherbenske M. J. (eds.): Benign prostatic hypertrophy, p. 101, DHEW Publ. No. (NIH) 76-1113, US Gov't Printing Office, Washington, DC, 1976.

Tveter A. J. : Some aspects of the pathogenesis of prostatic hyperplasia. Acta Pathol. Biol. Scand. (Suppl.), 248; 167 (1974).

Siiteri P. K. , Wilson J. D. : Dihydrotestosterone in prostatic hypertrophy. J. Clin. Invest, 49; 1737 (1970).

Scott W. W. , de Klerk D. P. : Benign prostatic hyperplasia: current status of medical treatment. In: Grayhack J. T. , Wilson J. D. , Scherbenske M. J. (eds.): Benign prostatic hypertrophy, p. 135, DHEW Publ. No. (NIH) 76-1113, US Gov't Printing Office, Washington, DC, 1976.

Paulson D. F. , Kane R. D. : Medrogestone: a prospective study in the pharmaceutical management of benign prostatic hyperplasia. J. Urol., 113; 811 (1975).

Stenger A. , Tarayre J. P. , Carilla E. , Delhon A. , Charveron M. , Morre M. , Lauressergues H. : Etude pharmacologique et biochimique de l'extrait hexanique de Serenoa Repens B’ (PA109). Gaz. Med. France, 89; 2041 (1982).

Briley M. , Carilla E. , Roger A. : Inhibitory effect of Permixon on testosterone 5α-reductase activity on the rat prostate. Brit. J. Pharmacol., 83; 401 (1984).

Carilla E. , Briley M. , Fauran F. , Sultan C. , Duvilliers C. : Binding of Permixon, a new treatment for benign prostatic hyperplasia, to the cytosolic androgen receptor in the rat prostate. J. Steroid. Biochem, 20; 521 (1984).

Scott W. W. , Coffey D. S. : Nonsurgical treatment of human benign prostatic hyperplasia. Vitam. Horm, 33; 439 (1975).

Monzer M. Adu-Yousef , Ambati S. N. : Transabdominal ultrasound in the evaluation of prostate size. J. Clin. Ultrasound, 10; 275 (1982).

Bartsch F. , Frick J. , Ruegg I. , Bucher M. , Holliger O. , Oberholzer M. , Rohr H. P. : Electron microscopic stereological analysis of the normal human prostate and of benign prostate hyperplasia. J. Urol., 122; 481 (1979).

Bartsch G. , Muller H. R. , Oberholzer M. , Rohr H. P. : Light microscopic stereological analysis of the normal human prostate and of benign prostate hyperplasia. J. Urol., 122; 487 (1979).

Sirett D. A. N , Cowan S. K. , Janeczko A. E. , Grant J. K. , Glen E. E. : Prostatic tissue distribution of 17ß-hydroxy-5α-androstan-3-one and of androgen receptors in benign hyperplasia. J. Steroid. Biochem, 13; 723 (1980).

Bruchovsky N. , Rennie P. S. , Wilkin N. P. : New aspects of androgen action in prostatic cells: stromal localization of 5α-reductase, nuclear abundance of androstanolone and binding of receptor to linker desoxyribonucleic acid. In: Schroeder F. H. , de Voogt H. J. (eds.): Steroid receptors, metabolism and prostatic cancer, p. 57. Excerpta Medica, Amsterdam 1980.

Bolton N. J. , Lahtenen R. , Hammond G. L. , Vihko R. : Distribution and concentrations of androgens in epithelial and stromal compartments of the human benign hypertrophic prostate. J. Endocrinol, 90; 125 (1981).

Geller J. , Albert J. , Lopez D. , Geller S. , Niwayama G. : Comparison of androgen mteabolites in benign prostatic hyppertrophy (BPH) and normal prostate. J. Clin. Endocrinol. Metabol, 43; 688 (1976).

Hammond G. L. : Endogenous steroid levels in the human prostate from birth to old age: a comparison of normal and diseased tissues. J. Endocrinol, 78; 7 (1978).

Schweikert H. U. , Totzauer P. , Rohr H. P. , Bartsch G. : Correlated biochemical and stereological studies on testosterone metabolism in the stromal and epithelial compartment of human benign prostatic hyperplasia. J. Urol., 134; 403 (1985).

McLoughlin M. G. , Bruchovsky N. : Stromal-epithelial interaction. In: Hinman F. jr. (ed.): Benign prostatic hypertrophy, p. 130, Springer-Verlag, New York 1983.

Bruchovsky N. , Lieskovsky G. : Increased ratio of 5α-reductase: 3α(ß)-hydroxysteroid dehydrogenase activities in the hyperplastic human prostate. J. Endocrinol, 80; 289 (1979).

McNeal J. E. : Origin and evolution of benign prostatic enlargement. Invest. Urol., 15; 340 (1978).

McNeal J. E. : New morphologic findings relevant to the origin and evolution of carcinoma of the prostate and BPH. In: Coffey D. S. , Isaacs J. T. (eds.): Prostate Cancer, UICC Techn. Rep. Ser. Geneva, 48; 24 (1979).

Cunha G. R. , Chung L. W. K. : Stromal-epithelial interactions. I. Induction of prostatic phenotype in urothelium of testicular feminized (Tfm/Y) mice. J. Steroid. Biochem., 14; 1317 (1981).

Cunha G. R. , Lung B. , Reese B. : Glandular epithelial induction by embryonic mesenchyme in adult bladder epithelium of BALB/C mice. Invest. Urol., 17; 302 (1980).

Cunha G. R. , Shannon J. N. , Neubauer B. L. , Sawyer L. M. , Fujii H. , Taguchi O. , Chung L. W. K. : Mesenchymal-epithelial interactions in sex differentiation. Hum. Genet., 58; 68 (1981).

Nagai N. , Longoope C. : Estradiol-17 ß and estrone: studies on their binding to rabbit uterine cytosol and their concentration in plasma. Steroids, 17; 631 (1971).

Kreig M. Klotzl G. , Kaufmann G. , Voigt K. D. : Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and oestrogen binding. Acta Endocrinol., 96; 422 (1981).

Cabot A. T. : The question of castration for enlarged prostate. Ann. Surg., 24; 265 (1896).

Griffiths J. : An enlarged prostate gland eighteen days after bilateral or complete castration. Brit. med. J., 1; 579 (1895).

White J. V. : The results of double castration in hypertrophy of the prostate. Ann. Surg., 22; 1 (1895).

Wendel E. F. , Brannen G. E. , Putong P. B. , Grayhack J. T. : The effect of orchiectomy and estrogens on benign prostatic hyperplasia. J. Urol., 108; 116 (1972).

Scott W. W. , Wade J. C. : Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J. Urol., 202; 81 (1969).

Caine M. , Perlberg S. , Gordon R. : The treatment of benign prostatic hypertrophy with flutamide (SCH 13521) a placebo-controlled study. J. Urol., 114; 564 (1975).

Geller J. , Adler E. H. , Albert J. , Brown D. W. , Licudan A. , Manaig E. : Using antiandrogen therapy in benign prostatic hyperplasia. Geriatrics, 32; 63 (1977).

Geller J. , Bora R. , Roberts T. , Newman H. , Silva R. : Treatment of benign prostatic hypertrophy with hydroxyprogesterone caproate. J.A.M.A., 193; 115 (1969).

Geller J. , Angrist A. , Nakao K. , Newman H. : Therapy with progestional agents in advanced benign prostatic hypertrophy. J.A.M.A., 220; 1421 (1969).

Rangno R. E. , McLeod P. J. , Ruedy J. , Ogilvie R. I. : Treatment of benign prostatic hypertrophy with medrogestone. Clin. Pharmacol. Ther., 12; 658 (1971).

Castro J. E. , Griffiths H. J. L. , Edwards D. W. : A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy. Brit. J. Surg., 58; 485 (1971).

Di Silverio F. , Tenaglia R. , Ferraro F. , Pannunzio E. , D'Eramo G. , Cerulli C. : La terapia ormonale dell'adenoma prostatico con cyproterone acetato (CPA) e tamoxifene (TAM). Atti 56° Congr. Soc. Ital. Urol., p. 489, Verona 1983.

Rohr H. P. , Bartsch G. : Stereological analysis. An approach to the pathogenesis of benign prostatic hyperplasia: current concepts. In: James V. H. T. (ed.): Proceedings of the V Intern. Congr. Endocrinology, Hamburg, Excerpta Medica Intern. Congr. Series, p. 495, No. 403 (1976).